<DOC>
	<DOCNO>NCT00359476</DOCNO>
	<brief_summary>The purpose study learn vinflunine shrink slow growth cancer patient advance metastatic stomach cancer progress prior treatment fluoropyrimidine taxane-containing chemotherapy regimen . The safety treatment also study .</brief_summary>
	<brief_title>A Study Vinflunine Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients locally advance metastatic gastric adenocarcinoma , include adenocarcinoma gastroesophageal junction progress fluoropyrimidine taxanecontaining regimen combination one prior first line treatment . EGOC performance status 0,1 2 Men woman , 18 year age old Patients receive one previous systemic chemotherapy regimen set . Major abdominal surgery within 2 month surgery general anesthesia within 4 week Unresolved occlusive subocclusive intestinal disease significant chronic intestinal disease ( e.g . ulcerative colitis ) Prior radiation &gt; =30 % bone marrow and/or radiation within 4 week prior enrollment Acute chronic hepatitis Known HIV infection A mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m A history additional risk factor Torsade de Pointes ( e.g. , heart failure hypokalemia , family history Long QT Syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Locally advanced/metastatic gastric adenocarcinoma</keyword>
	<keyword>adenocarcinoma-gastroesophageal junction</keyword>
	<keyword>Gastric Adenocarcinoma</keyword>
</DOC>